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https://doi.org/1Background: Changes in renal function have been associated with differential outcomes in patients with
acute heart failure (HF). However, individual trajectories of changes in renal function are unknown, and it
is unclear whether they relate to different clinical characteristics and clinical outcomes. Our aim was to
investigate the prognostic importance of individual trajectories of change in renal function in acute HF.
Methods: This was a retrospective, observational analysis from the double-blind, randomized, placebo-
controlled PROTECT trial in patients with acute HF. We identified and internally validated 8 different
renal trajectories among 1897 patients by visual inspection of inhospital serum creatinine changes. The pri-
mary outcome measure was all-cause mortality at 180 days. Mean age was 70 § 12 years; 70% were male,
and mean baseline estimated glomerular filtration rate was 49.0 mL/min/1.73m2.
Results: A total of 8 different trajectories was established. The most prevalent trajectories were an inhos-
pital bump (19.0%), a sustained increase (17.6%) and a dip (14.5%) in serum creatinine. Overall, the clini-
cal characteristics of patients in different trajectories were remarkably similar. Crude 180-day mortality
rates ranged from 12.0% in the trajectory, with no significant changes to 18.3% in the trajectory of sus-
tained increase without significant differences. Overall, after multivariable adjustment, there was no trajec-
tory of changes in renal function that was associated with significantly better or worse outcomes.
Conclusions: Trajectories of changes in renal function in acute HF differ considerably on the patient level.
Despite these differences, clinical characteristics and outcomes were similar, therefore, questioning the
prognostic importance of changes in renal function in acute HF. (J Cardiac Fail 2019;25:866874)
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Acute heart failure (HF) is a major health care problem,
affecting nearly 1 million new patients per year. It is associ-
ated with poor clinical outcomes.14 When chronic kidney
disease (CKD), defined as an estimated glomerular filtration
rate (eGFR) of <60 mL/min/1.73m2, is present in acute HF,
it is associated with a 2-fold increased risk of mortality.5 In
addition to impaired baseline renal function, deterioration
in renal function or worsening renal function (WRF) duringersity of Groningen, Department of Cardiology, University Med
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866hospitalization is commonly observed in patients with acute
HF.57 In a meta-analysis, WRF was associated with an
increased risk of mortality and HF hospitalization in
patients with chronic HF who have both reduced and pre-
served ejection fraction.8 In acute HF, in which WRF
occurs in 20%30% of patients, deterioration was also
associated with a significantly increased mortality risk.5,9
On a population level, it has been shown that the mean
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ger inhospital stay, which is thought to be related to the
great diversity in renal changes in patients.10
However, it is questionable whether this analysis was
able to capture the individual heterogeneity of patterns of
renal function because we hypothesized that individual
renal trajectories do not strictly follow the trajectory in a
homogeneous population. Therefore, we evaluated the pres-
ence of distinct individual trajectories of change in renal
function in acute HF and investigated their associations
with clinical characteristics and outcomes in an analysis
from the Placebo-controlled Randomized Study of Selective
A1 Adenosine Receptor Antagonist Rolofylline for Patients
Hospitalized with Acute Decompensated Heart Failure and
Volume Overload to Assess Treatment Effect on Conges-
tion and Renal Function (PROTECT) study.Methods
Patients
The main design and findings of the PROTECT trial, a
multicenter, randomized, double-blind, placebo-controlled
phase III trial, have been published.11,12
In short, 2033 patients with acute (decompensated) HF
requiring IV diuretic therapy, with mild or moderate renal
impairment (estimated creatinine clearance between 20 and
80 mL/min), were randomized to Rolofylline or placebo.
The main findings were neutral. Crucial exclusion criteria
included a systolic blood pressure < 90 or  160 mmHg
and ongoing or planned treatment with ultrafiltration or
dialysis. All patients provided written informed consent.
For the purpose of this analysis, we included all patients in
the intention-to-treat population who were still alive at study
day 7, had  3 serum creatinine measurements taken within
the first 7 days of the study, had baseline creatinine measure-
ments, and had additional follow-up for death and rehospital-
ization of  7 days. Using these criteria, the sample size for
the present study was 1897 patients of the total study popula-
tion (93%). Serum creatinine was assessed in a central labo-
ratory (ICON Laboratories, Farmingdale, New York).Trajectory establishment and assessment
In a random sample of 200 patients of the population, 3
independent investigators (IB, KS, JTM) identified clusters
of different renal trajectories in a blinded (for outcome and
other characteristics) fashion. Each investigator looked at
the trajectories of individual patients while blinded to the
results of the other investigators. This was performed by
visual inspection of each patient’s individual pattern of
serum creatinine when printed on a Y-axis normalized for
individual patient absolute creatinine values. Then results
were pooled, and inconsistencies were solved by consensus,
including assessment by a fourth investigator (KD). This
resulted in 8 distinct different renal trajectories.
Subsequently, 2 researchers (IB, KS) individually
assigned each patient in the entire study population to 1 ofthe 8 trajectories in a blinded matter in a similar procedure.
Afterwards, results were pooled and inconsistencies were
solved by consensus, which again included assessment by a
third investigator (KD). To check whether the level of
agreement between the investigators was acceptable, inter-
observer agreement was measured by k statistics.Study outcomes
The primary outcome variable of interest was all-cause
mortality at 180 days. The secondary outcome included car-
diovascular or renal rehospitalization at 60 days and death
or rehospitalization for HF at 60 days.Statistical analysis
Symmetrically distributed continuous variables are pre-
sented as mean § standard deviation; skewed data are pre-
sented as median and 25th75th percentile. Categorical
variables are presented as numbers (percentage) (N[%]). Dif-
ferences in baseline characteristics were evaluated using appro-
priate statistics, such as ANOVA statistics (normal
distribution) or Kruskal-Wallis statistics (skewed data). Differ-
ences in proportions were assessed using x2 tests. Event rates
at the time points of interest are presented using percentages
and Kaplan-Meier figures. Logarithmic transformations were
applied to model nonlinear relationships. To evaluate the rela-
tionships among different trajectories and clinical outcomes, a
Cox proportional hazard analysis was performed. For each con-
tinuous predictor, the assumption of linearity was checked.
Multivariable adjustment was done in 2 steps. First, adjustment
for baseline eGFR (calculated by the CKD-EPI formula),13 and
second, a multivariable model based on a previously published
8-item prognostic model in this population, including the varia-
bles of age, systolic blood pressure, edema, previous history of
hospitalization for HF, baseline serum albumin, blood urea
nitrogen, creatinine, and sodium.14 Estimates are presented as
hazard ratios (HR) with 95% confidence intervals (CI). As a
sensitivity analysis and internal-validation step, we also evalu-
ated the trajectories of serum creatinine in each of the defined
trajectories by using a repeated measures, random effect model.
Two-tailed P values< 0.05 were considered statistically signif-
icant. Statistical analyses were performed using IBM SPSS Sta-
tistics v. 23 (Armonk, New York, USA) and R: a Language
and Environment for Statistical Computing, v. 3.0.2 (R Foun-
dation for Statistical Computing, Vienna, Austria).15Results
Population
The study population consisted of 1897 patients, of
whom 70% were male and had a mean age of 70§ 12 years,
a left ventricular ejection fraction of 32 § 13% and a base-
line eGFR of 49 § 20 mL/min/1.73m2. Median diuretic
response over 4 days was 0.39 (0.80 to 0.14) kg/
40 mg furosemide.
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First, we identified 8 renal trajectories identified by
changes in creatinine, as seen in Figure 1. These included a
drop followed by a rise (Dip), a rise followed by a drop
(Bump), a Dip followed by Bump, a Bump followed by
Dip, a Sustained Decrease, a Sustained Increase, an (almost)
absence of change (No Change) and, finally, multiple sig-
nificant fluctuations (Various Changes) that fitted none of
the other trajectories.
The k value for the pilot study (200 patients) was 0.82
(0.770.86, 95% CI), correlating with a strong level of
agreement. After all 1897 patients were categorized into 1
of the 8 trajectories, the k value was 0.85 (0.830.86, 95%
CI). In a sensitivity analysis, we retrospectively evaluated
the trajectories of creatinine in each of the defined trajecto-
ries. The results of this validation step are shown in Supple-
mentary Figure 1. This confirms the general slope of
creatinine on a group level within each trajectory, with the
exception of the Various Changes trajectory, which proba-
bly represents a mixed bag, with individual changes in cre-
atinine that, on a group level, oppose one another, resulting
in a horizontal slope.
The distribution of the prevalence of different trajectories
is shown in Figure 1; it ranges from 50 (2.6%) in No
Change to 360 (19.0%) in Bump.
Baseline characteristics
Baseline characteristics of the different trajectories are
shown in Table 1. Overall, the characteristics of different
trajectories were similar, and only small differences wereFig. 1. Prevalence and visual representation of differing trajectories of c
rise followed by a drop; Dip followed by Bump: a drop followed by a rise
drop and a subsequent rise; Sustained Decrease: a continuous decrease; S
absence of change; Various Changes: multiple significant fluctuations (noobserved. Notably, patients with the trajectory No Change
were more likely to be male and had the highest body mass
indexes, whereas patients with trajectory Sustained Increase
were the oldest. The trajectory Sustained Decrease included
patients who had the lowest left ventricular ejection fraction
(31% § 13%) and most commonly were in New York Heart
Association class IV (44%). Mean baseline eGFR, was low-
est in this group, with a corresponding creatinine value of
1.60 (1.302.10) mg/dL. The trajectory Dip followed by
Bump included patients who had the highest prescription
rates of angiotensin converting enzyme (ACE) inhibitors.
Regarding clinical symptoms, severe dyspnea was most
commonly present in patients included in trajectory Dip
(88.8%). The trajectories of Sustained Increase, Bump and
No Change showed the worst diuretic responses: 0.33
(0.78 to 0.10), 0.33 (0.70 to 0.11), and 0.26
(0.47 to 0.14) kg/40 mg furosemide, respectively. The
best diuretic response was found in the trajectory Various
Changes: 0.46 (0.97 to 0.16) kg/40 mg furosemide
(P value = 0.001). Hemoconcentration, defined as an
increase in hemoglobin from admission to day 7 (or dis-
charge) varied between 48% (Drop) and 67% (Pancake) but
was not significantly different between trajectories.Renal trajectories and clinical outcomes
During follow-up, 301 (15.9%) of 1897 patients experi-
enced the primary outcome of all-cause mortality at day
180. Among all renal trajectories, differences in mortality
were small and not significantly different. In the trajectory
with a sustained increase in creatinine, 61 patients (18.3%)hanges in renal function. Dip: a drop followed by a rise; Bump: a
and subsequent drop; Bump followed by Dip: a rise followed by a
ustained Increase: a continuous increase; No Change: an (almost)
t fitting other trajectories).
Table 1. Baseline Characteristics
Trajectory Bump
Sustained
increase Dip
Sustained
decrease
Various
changes
Dip followed
by Bump
Bump followed
by Dip No change P Value
N = 1897 N = 360 N = 333 N = 275 N = 264 N = 245 N = 208 N = 162 N = 50
Demographics
Sex (% male) 242 (67) 217 (65) 176 (64) 182 (69) 167 (68) 138 (66) 106 (65) 42 (84) 0.254
Age (years) 70 § 12 72 § 11 70 § 12 70 § 11 69 § 12 68 § 12 70 § 11 68 § 13 0.064
Race (% white) 337 (94) 310 (94) 266 (97) 247 (94) 238 (98) 200 (97) 154 (96) 47 (94) 0.150
Weight (kg) 80 § 18 83 § 19 82 § 20 82 § 20 83 § 20 83 § 18 78 § 17 91 § 23 0.002
Height (cm) 168 § 9 169 § 9 169 § 9 169 § 10 169 § 9 169 § 9 167 § 10 170 § 8 0.253
Body mass index 29 § 6 29 § 6 29 § 7 29 § 6 29 § 6 29 § 6 28 § 5 31 § 7 0.026
LVEF (%) 32 § 13 33 § 13 32 § 12 31 § 13 32 § 14 33 § 13 33 § 13 31 § 14 0.638
SBP (mmHg) 125 § 17 127 § 19 124 § 17 121§ 17 124 § 18 124 § 17 126 § 19 124 § 16 0.020
DBP (mmHg) 75 § 11 73 § 13 74 § 11 73§ 12 75 § 12 75 § 11 73 § 12 72 § 11 0.050
Heart rate (beats/min) 80 § 15 79 § 15 80 § 16 81§ 17 81 § 16 82 § 15 79 § 16 80 § 13 0.130
Medication
ACE inhibitor 234 (65) 181 (54) 165 (60) 174 (66) 158 (65) 139 (67) 103 (64) 27 (54) 0.025
ARB 52 (14) 82 (25) 45 (16) 32 (12) 28 (11) 25 (12) 24 (15) 9 (18) <0.001
Beta-blocker 273 (76) 254 (76) 219 (80) 199 (75) 184 (75) 165 (79) 121 (75) 43 (86) 0.574
Nitrates 84 (23) 91 (27) 58 (21) 79 (30) 69 (28) 59 (28) 36 (22) 12 (24) 0.199
Ca channel blocker 53 (15) 60 (18) 33 (12) 27 (10) 23 (9) 26 (13) 25 (15) 10 (20) 0.033
MRA 159 (44) 148 (44) 111 (40) 115 (44) 107 (44) 105 (51) 74 (46) 24 (48) 0.607
Medical history
Angina (N(%)) 79 (22) 67 (20) 57 (21) 65 (25) 65 (27) 45 (22) 33 (21) 9 (18) 0.572
AF 185 (51) 166 (50) 160 (59) 160 (61) 131 (54) 107 (52) 87 (55) 28 (60) 0.126
Smoking 71 (20) 81 (24) 53 (19) 52 (20) 54 (22) 37 (18) 32 (20) 14 (28) 0.500
NYHA <0.001
I/II 64 (19) 81 (26) 46 (18) 26 (10) 42 (18) 30 (15) 25 (16) 6 (12)
III 174 (51) 169 (54) 139 (54) 116 (46) 120 (52) 94 (47) 79 (51) 28 (56)
IV 103 (30) 65 (21) 75 (29) 111 (44) 69 (30) 75 (38) 50 (33) 16 (32)
Diabetes mellitus 153 (43) 157 (47) 138 (50) 115 (44) 115 (47) 92 (44) 68 (42) 25 (50) 0.540
Hypertension 277 (77) 281 (84) 213 (78) 214 (81) 192 (78) 173 (83) 123 (76) 36 (72) 0.090
Ischemic HD 249 (69) 247 (74) 194 (71) 181 (69) 154 (63) 144 (69) 110 (68) 41 (82) 0.092
MI 174 (48) 180 (54) 139 (51) 130 (49) 107 (44) 105 (51) 77 (48) 32 (64) 0.157
PCI 92 (26) 112 (34) 74 (27) 59 (23) 54 (22) 42 (20) 35 (22) 23 (47) <0.001
Stroke (beyond 2 yrs) 26 (7) 33 (10) 23 (8) 27 (10) 17 (7) 22 (11) 17 (11) 7 (14) 0.521
Biomarkers
Albumin (g/dL) 3.9 (3.74.2) 3.9 (3.64.1) 3.9 (3.74.1) 3.8 (3.64.1) 3.9 (3.6-4.2) 3.8 (3.64.15) 3.9 (3.64.2) 3.8 (3.64.15) 0.005
Chloride (mEq/L) 101 (98105) 102 (99105) 101 (99104) 101 (97-105) 102 (99104) 102 (99104) 102 (97104) 102 (100106) 0.035
Cholesterol, total (mg/dL) 148 (123180) 146 (115176) 141 (117163) 132 (107164) 158 (127188) 147 (122168) 152 (125185) 146 (124171) 0.001
Glucose, random, Serum (mg/dL) 127 (97164) 123 (103154) 146 (117207) 124 (102-167) 133 (106175) 133 (108181) 117 (92138) 133 (121191) 0.004
Potassium (mEq/L) 4.2 (3.94.6) 4.2 (3.84.6) 4.3 (3.94.7) 4.4 (3.9-4.9) 4.2 (3.94.7) 4.2 (3.94.7) 4.25 (3.94.6) 4.5 (3.954.85) 0.097
Sodium (mEq/L) 140 (138142) 140 (138143) 140 (137143) 139 (137-142) 141 (138143) 140 (138142) 139 (137142) 140 (139143) 0.012
Uric acid (mg/dL) 8.4 (6.810.4) 8.8 (7.210.3) 8.8 (7.410.5) 9.4 (7.611.3) 7.9 (6.4-10.1) 8.8 (7.110.1) 8.5 (7.210.1) 9.1 (6.810.3) <0.001
eGFR (mL/min/1.73m2) 50.66 § 20.75 49.14 § 20.26 50.22 § 19.59 43.63 § 16.27 56.47 § 21.92 51.12 § 18.57 55.59 § 20.50 54.06 § 22.26 <0.001
Creatinine (mg/dL) 1.40 (1.10150) 1.40 (1.101.80) 1.40 (1.101.70) 1.60 (1.302.10) 1.20 (1.101.50) 1.40 (1.101.80) 106 (1.001.50) 1.50 (1.202.00) <0.001
Hct (%) 40.2 § 6.2 38.7§ 5.6 40.5 § 6.3 40.5 § 6.2 41.6 § 6.2 40.9 § 6.4 40.3 § 6.2 40.2 § 5.5 <0.001
Hgb (g/dL) 12.7 § 1.9 12.2§ 1.8 12.7 § 2.0 12.7 § 2.0 13.2 § 2.0 12.8 § 2.0 12.9 § 2.1 12.6 § 1.9 <0.001
BUN (mg/dL) 28 (2239) 31 (2238) 30 (22-42) 37 (2650) 27 (2135) 29 (2140) 25 (2035) 29 (2238) <0.001
BNP (pg/mL) 406 (248735) 408 (247694) 440 (267-860) 612 (2961007) 432 (253745) 484 (257797) 415 (266780) 443 (219654) 0.002
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870 Journal of Cardiac Failure Vol. 25 No. 11 November 2019experienced the primary endpoint of all-cause mortality. In
the trajectory of sustained decrease, which represents the
opposite of the sustained increase trajectory, 48 patients
(18.2%) experienced the primary outcome. Notably, the tra-
jectory with almost an absence of change in renal function,
No Change, had the lowest mortality rate; 6 patients
(12.0%) experienced all-cause mortality at 180 days.
The Kaplan-Meier figure for the primary outcome, mor-
tality at 180 days, among renal trajectories is depicted in
Figure 2 (logrank P value of 0.51) and showed, in general,
similar outcomes for all groups.
In Cox regression analysis, using the trajectory No
Change as the reference category (no change in serum creat-
inine, which showed the best outcome in the Kaplan-Meier
survival analysis), the highest mortality risk was observed
in both the trajectory Sustained Decrease (HR 1.58, 95% CI
0.68 to 3.70) and the trajectory Sustained Increase (HR
1.59, 95% CI 0.69 to 3.68). However, these differences did
not reach statistical significance (P value 0.29 and 0.28,
respectively) (Table 2). Other trajectories showed a similar
pattern, without evidence of increased or decreased risk
with any particular trajectory.
In multivariable Cox regression analysis, after adjust-
ment for baseline eGFR, similar findings remained
(Table 2). Whereas eGFR at baseline itself was a powerful
predictor of mortality, none of the trajectories showed a sig-
nificant association with increased mortality rates. Even
when adjusted for baseline diuretic response, no significant
differences were found. Finally, after adjustment for the 8
variable multivariable model previously published from
this population, the results remained largely unchanged.
The secondary combined endpoint of death or cardiovas-
cular or renal rehospitalization at day 60 (Figure 3) showed
similar results for all trajectories. However, a trend was
observed in favor of the fluctuating trajectory Various
Changes regarding all the secondary outcomes in unad-
justed analyses, whereas the trajectory No Change showed
the worst outcomes. However, in Cox regression analysis
and after multivariable adjustment, no statistically signifi-
cant differences among the trajectories were observed.Discussion
This study was designed to identify patterns of changes in
renal function during a hospital admission for acute HF and
to relate these patterns to differing clinical characteristics
and outcomes. Our results show that despite marked differ-
ences in patterns, as determined on an individual patient
level, differences in clinical characteristics and clinical out-
comes were small.Epidemiology of renal trajectories
In acute heart failure, 20%30% of patients experience
deterioration or worsening renal function during hospitaliza-
tion.5,16 This mean change in renal function in a population
with HF is reflected by an increase in serum creatinine that
Fig. 2. Differing trajectories and Kaplan-Meier plot of all-cause mortality at 180 days.
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because the overall characteristics of the population with
acute heart failure have great heterogeneity, this may also
hold true for patterns of changes in renal function.17 More
evidence of this heterogeneity of the population with HF is
also stressed by a recent meta-analysis, in which findings
suggest that not only the clinical setting, but also the cause of
WRF and associated hemodynamic changes, are of major
importance for evaluating the significance of WRF.5 In a
smaller study of 401 patients with with acute decompensated
HF, WRF occurred in 21.2% (defined as  20% change in
eGFR), while also showing that an improvement in renal
function (identified by a decrease in creatinine, similar to the
trajectory Sustained Decrease in our study) occurred in
16.2% of the population.18 Overall, in this small study, the
baseline characteristics of both worsening and improving
renal function were similar.19 Despite the innovative compar-
ison of the assessment of 2 opposing renal-function changes,
the focus of these particular analyses were still on the change
in renal function on a population level. One possible explana-
tion was put forward by Kataoka, suggesting that
“paradoxicalˮ improvement of renal function, as reflected by
a decrease in serum creatinine despite worsening HF, could
be due to interindividual differences in renal function among
patients. Moreover, most studies have used merely 2 time
points of measurements of serum creatinine to quantify
changes in renal function, instead of using severalmeasurements to form a realistic slope.5,20,21 Therefore, in
this present study, we thoroughly evaluated each individual
renal trajectory and subsequently identified 8 distinct trajec-
tories of changes of renal function. Of these patterns, a rise
in creatinine followed by a drop (trajectory Bump) was most
prevalent, whereas almost an absence of change in creatinine
(trajectory No Change) was least common. Interestingly, the
2 most opposing trajectories, a sustained increase vs a sus-
tained decrease, had similar baseline characteristics. Overall,
baseline differences among all trajectories were remarkably
small, despite the great diversity in the individual changes in
renal function patterns. Therefore, it might be difficult to
establish specific characteristics that identify beforehand
which patients will experience similar patterns of change in
renal function.Clinical outcomes and patterns of change in renal
function
In general, WRF in acute HF has been associated with
worse clinical outcome because it is independently associated
with significantly increased mortality and rehospitalization
risks.5,22 However, this does not directly imply that the likeli-
hood of survival improves if treatment causes improvement
in serum creatinine changes. On the contrary, it has been
shown that also improved renal function, as shown by a
decrease in serum creatinine, is associated with a significant,
Table 2. Cox Survival Analysis for Predicting 180-Day Mortality
Trajectory Number of patients N (%) HR (95% CI) P Value HR (95% CI)* P Value HR (95% CI)y P Value
No change 50 Ref. 0.52 Ref. 0.57 Ref. 0.46
Bump 360 1.35 (0.583.13) 0.48 1.40 (0.603.24) 0.43 1.53 (0.663.57) 0.32
Sustained increase 333 1.59 (0.693.68) 0.28 1.57 (0.683.63) 0.29 1.59 (0.683.69) 0.28
Dip 275 1.24 (0.532.93) 0.62 1.24 (0.522.92) 0.63 1.27 (0.543.02) 0.58
Sustained decrease 264 1.58 (0.683.70) 0.29 1.41 (0.603.30) 0.43 1.19 (0.512.79) 0.69
Various changes 245 1.43 (0.613.36) 0.42 1.67 (0.713.93) 0.24 1.74 (0.734.13) 0.21
Dip followed by Bump 208 1.00 (0.412.44) 1.00 1.02 (0.422.49) 0.96 1.11 (0.452.73) 0.82
Bump followed by Dip 162 1.22 (0.502.99) 0.68 1.38 (0.563.40) 0.49 1.45 (0.593.59) 0.42
*Model 2. Renal trajectories adjusted for estimated GFR.
yModel 3. Renal trajectories adjusted for age of subject, systolic blood pressure, heart failure hospitalization in past year, severity of edema, baseline albu-
min (g/dL), sodium (mEq/L), blood urea nitrogen (BUN) (mg/dL), and creatinine (mg/dL).
872 Journal of Cardiac Failure Vol. 25 No. 11 November 2019independent, increased risk of mortality, and WRF in the con-
text of hemoconcentration is not associated with worse out-
comes.7,18,23 Furthermore, the important role of individual
risk factors and biomarkers is emphasized; they provide more
prognostic information than the sum of population risk fac-
tors.24 Therefore, this present study investigated the prognos-
tic role of the trajectory of serum creatinine as an individual
renal marker. Overall, our study found that differences in all-
cause mortality were small, even when adjusted for baseline
eGFR. The individual renal pattern that is considered to be
“true” WRF, a continuous increase in creatinine (Sustained
Increase) had unexpectedly similar outcomes when compared
to the opposing trajectory, a constant decrease in creatinine
(Sustained Decrease), or so-called improved renal function.Fig. 3. Differing trajectories and Kaplan-Meier plot of deathWe were also unable to find other statistically significant dif-
ferences in clinical outcome for any of the trajectories, for all-
cause mortality and the secondary outcomes. Although small
differences were observed in crude event rates, it is question-
able whether this translates into clinically relevant changes.
Overall, we found no significant evidence for an increased or
decreased risk with any particular trajectory.Possible explanations and clinical implications
There are several possible explanations for the present
findings. One explanation could be the impact of changes in
treatment strategies, which were based on either changes in
renal function or actually caused the changes in renalor cardiovascular or renal rehospitalization at 60 days.
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function during treatment of acute HF and probably act on
these changes in response to therapy. Our findings are,
therefore, a reflection of the general course of creatinine,
together with the effect of (changes in) decongestive strate-
gies. In this way, perhaps, by adjusting therapies, physicians
may have overcome some of the excess of risk that has been
associated with WRF in acute heart failure. Second, it is
known that patients with HF commonly experience deterio-
ration in renal function prior to hospital admission, as well
as posthospital recurrence of renal dysfunction.18,25 This
means that the observed inhospital changes in creatinine
may be only a reflection of a small part of the entire time-
frame in which serum creatinine levels may change. Fur-
thermore, renal function changes should always be
evaluated together with the clinical course of the patient.22
However, diuretic response,26 serving as a surrogate for the
clinical course, was not particularly different among trajec-
tories and did not impact the association between trajecto-
ries and clinical outcomes.Strengths and limitations
The novelty of this present study is the use of individual
patient data to define the patterns and trajectories of renal
function. Individual patient data most accurately reflect real
clinical practice. Nevertheless, this is a post hoc analysis,
and our findings should, therefore, be considered hypothe-
sis-generating only. Our study was conducted in a cohort of
a randomized controlled trial, in which treating physicians
were unblinded to serum creatinine values and could have
consequently altered their treatment regimes, resulting in
altered risks among patients. The inclusion and exclusion
criteria of this randomized controlled trial may have
resulted in selection bias, possibly inducing type I error.
Furthermore, our results are limited by the data available,
as our analysis only includes the first 7 days of inhospital
events and, therefore, excludes events prior to hospitaliza-
tion or after discharge. For example, a patient with HF who
experiences a continuous decrease in creatinine during the
first 7 days after admission might experience a change in
renal function after discharge, unknowingly altering the
individual risk of mortality. It is still difficult to characterize
accurately renal function in acute HF, which could mean
that serum creatinine changes in the acute phase do not
reflect changes in renal function. Furthermore, trajectory
assessment was performed by visual inspection and might
result in a different distribution in the trajectory groups
when reproduced by different investigators. Additionally,
we did not include the magnitude of change in creatinine in
our analysis because we focused on the relative change
(visual trajectories). The trajectory Various Changes proba-
bly represents a mixed bag of differing changes in serum
creatinine because the overall changes in creatinine in sen-
sitivity analysis were limited. Given the large number of
defined trajectories and the known random variation due tothe creatinine assay or random sampling variation, the true
changes in creatinine levels in each patient could have been
over- or underestimated. Finally, to establish more than 1
fluctuation in creatinine, more than 4 serum creatinine val-
ues should be available; therefore, the prevalence of the tra-
jectories Various Changes, Bump followed by Dip and Dip
followed by Bump may have been underestimated.
Conclusions
Although there are major differences in patterns of
changes in renal function during a hospital admission result-
ing from acute HF, clinical characteristics and clinical out-
comes were similar in the trajectories. Our results,
therefore, question the prognostic importance of patterns of
changes in renal function in acute HF.
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